ArticleVaccine2011
Intranasal delivery of Norwalk virus-like particles formulated in an in situ gelling, dry powder vaccine.
Article in Vaccine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.
- A decade of norovirus disease risk among older adults in upper-middle and high income countries: a systematic review.BMC infectious diseases · 2015Pooled it
- Glycoconjugate vaccines: platforms and adjuvants for directed immunity.Glycobiology · 2024Review
- Main Aspects of Pharmaceutical Development ofCurrent pharmaceutical biotechnology · 2024Review
- Chrysanthemum sporopollenin: A novel vaccine delivery system for nasal mucosal immunity.Frontiers in immunology · 2023Article
- Development and application of ribonucleic acid therapy strategies against COVID-19.International journal of biological sciences · 2022Review
- Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies.Biomolecules · 2021Review
- Oral Immunization With a Plant HSP90-SAG1 Fusion Protein Produced in Tobacco Elicits Strong Immune Responses and Reduces Cyst Number and Clinical Signs of Toxoplasmosis in Mice.Frontiers in plant science · 2021Article
- Prospects for RNAi Therapy of COVID-19.Frontiers in bioengineering and biotechnology · 2020Review
- Novel approaches for the design, delivery and administration of vaccine technologies.Clinical and experimental immunology · 2019Review
- Human Norovirus: Experimental Models of Infection.Viruses · 2019Review
- Intranasal immunization with aluminum salt-adjuvanted dry powder vaccine.Journal of controlled release : official journal of the Controlled Release Society · 2018Article
- Therapeutics and Immunoprophylaxis Against Noroviruses and Rotaviruses: The Past, Present, and Future.Current drug metabolism · 2018Review
- Intranasal immunization with dry powder vaccines.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2018Review
- Article
- Prospects and Challenges in the Development of a Norovirus Vaccine.Clinical therapeutics · 2017Review
- Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder.PloS one · 2017Article
- Co-delivery of GPI-anchored CCL28 and influenza HA in chimeric virus-like particles induces cross-protective immunity against H3N2 viruses.Journal of controlled release : official journal of the Controlled Release Society · 2016Article
- Optimized Formulation of a Thermostable Spray-Dried Virus-Like Particle Vaccine against Human Papillomavirus.Molecular pharmaceutics · 2016Article
- Article
- Current Advances in Virus-Like Particles as a Vaccination Approach against HIV Infection.Vaccines · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
The development of a vaccine to prevent norovirus infections has been focused on immunization at a mucosal surface, but has been limited by the low immunogenicity of self-assembling Norwalk virus-like particles (NV VLPs) delivered enterically or at nasal surfaces. Nasal immunization, which offers the advantage of ease of immunization, faces obstacles imposed by the normal process of mucociliary clearance, which limits residence time of applied antigens. Herein, we describe the use of a dry powder formulation (GelVac) of an inert in situ gelling polysaccharide (GelSite) extracted from Aloe vera for nasal delivery of NV VLP antigen. Powder formulations, with or without NV VLP antigen, were similar in structure in dry form or when rehydrated in simulated nasal fluids. Immunogenicity of the dry powder VLP formulation was compared to equivalent antigen/adjuvant liquid formulations in animals. For the GelVac powder, we observed superior NV-specific serum and mucosal (aerodigestive and reproductive tracts) antibody responses relative to liquid formulations. Incorporation of the TLR7 agonist gardiquimod in dry powder formulations did not enhance antibody responses, although its inclusion in liquid formulations did enhance VLP immunogenicity irrespective of the presence or absence of GelSite. We interpret these data as showing that GelSite-based dry powder formulations (1) stabilize the immunogenic structural properties of VLPs and (2) induce systemic and mucosal antibody titers which are equal or greater than those achieved by VLPs plus adjuvant in a liquid formulation. We conclude that in situ gelation of the GelVac dry powder formulation at nasal mucosal surfaces delays mucociliary clearance and thereby prolongs VLP antigen exposure to immune effector sites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.